Zacks Small Cap Has Strong Estimate for COCP FY2025 Earnings

Cocrystal Pharma, Inc. (NASDAQ:COCPFree Report) – Research analysts at Zacks Small Cap raised their FY2025 earnings per share (EPS) estimates for shares of Cocrystal Pharma in a note issued to investors on Tuesday, May 27th. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($1.48) per share for the year, up from their previous forecast of ($1.65). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share.

Cocrystal Pharma (NASDAQ:COCPGet Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.29.

Cocrystal Pharma Trading Up 9.7%

NASDAQ COCP opened at $1.70 on Thursday. The stock has a market cap of $17.29 million, a PE ratio of -0.92 and a beta of 2.13. Cocrystal Pharma has a twelve month low of $1.12 and a twelve month high of $3.26. The stock has a fifty day simple moving average of $1.44 and a 200-day simple moving average of $1.81.

Cocrystal Pharma Company Profile

(Get Free Report)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.

Featured Articles

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.